Best percentage change from baseline in target lesion size. (A) Patients receiving the PI3Kδ inhibitor INCB040093 alone. (B) Patients receiving INCB040093 combined with the JAK1 inhibitor itacitinib. Included are patients with data available for best percentage change from baseline in target lesion size (monotherapy, n = 45; combination therapy, n = 55). The upper dotted line corresponds to criteria for PD (at least 50% increase) and lower to PR (at least 50% decrease). PD indicates PD or relapsed disease (after CR). Patients with ¹⁸F-FDG–avid lymphoma who were PET-positive at baseline could achieve a CR without complete resolution of the target lesion if the lesion became PET-negative per the Revised Response Criteria for Malignant Lymphoma.²³ *Patient was not evaluable for response; the target lesion size was from an assessment, which was 7 days after starting treatment; no other on-study assessment was available. †Best percentage change from baseline in target lesion size >100%.